SCHEMBL25614497

SCHEMBL25614497

C#Cc1cncc(-n2ccnc2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.47
CYP2A6 P11509 1/20 0.47
CYP11B1 P15538 2/20 0.43
CYP11B2 P19099 2/20 0.43
CYP19A1 P11511 2/20 0.41
CHRNB4 P30926 5/20 0.41
CHRNA3 P32297 5/20 0.41
CHRNB2 P17787 4/20 0.41
CHRNA4 P43681 4/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
ENPP2 Q13822 1/20 0.41
MKNK1 Q9BUB5 1/20 0.41
MKNK2 Q9HBH9 1/20 0.41
NOTUM Q6P988 1/20 0.41
IDO1 P14902 1/20 0.40
MEN1 O00255 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30811647 1.00 CYP3A4 (0.47) CYP3A4CYP2A6CYP11B1CYP11B2CYP19A1
SCHEMBL30463031 0.81 CYP3A4 (0.61) CYP3A4CYP2A6CYP11B1CYP11B2CYP19A1
SCHEMBL30811672 0.80 CHRNA3 (0.44) CYP2A6CHRNB4CHRNA3CHRNB2CHRNA4
SCHEMBL25614130 0.80 CHRNB2 (0.48) CYP2A6CHRNB4CHRNA3CHRNB2CHRNA4
SCHEMBL25614551 0.80 CHRNA3 (0.44) CYP2A6CHRNB4CHRNA3CHRNB2CHRNA4
SCHEMBL16311717 0.78 IDO1 (0.58) CYP3A4CYP2A6CYP11B1CYP11B2CYP19A1
SCHEMBL25614496 0.78 CYP3A4 (0.42) CYP3A4CYP2A6CYP11B1CYP11B2CYP19A1
SCHEMBL31606763 0.77 LMNA (0.58) CYP3A4CYP2A6CYP11B1CYP11B2CYP19A1
SCHEMBL1559218 0.73 CYP3A4 (0.52) CYP3A4CYP2A6CYP11B1CYP11B2CYP19A1
SCHEMBL25614467 0.73 CHRNA3 (0.44) CYP2A6CHRNB4CHRNA3CHRNB2CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4582422-A1 METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF Global Health Drug Discovery Institute (CN) 2025-07-09 EP disclosed
US-20250214997-A1 METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF GLOBAL HEALTH DRUG DISCOVERY INSTITUTE (CN) 2025-07-03 US disclosed
WO-2024056099-A1 METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF 北京华益健康药物研究中心 2024-03-21 WO disclosed
WO-2023104209-A1 METTL3 INHIBITOR COMPOUND 上海昂阔医药有限公司 2023-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214997-A1 METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF METTL3, METTL14, METTL16 CYP3A4 116/4885CYP2A6 887/4885CYP11B1 200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.